Global Antivenom 麻豆原创 Growth 2025-2031

Publication ID:

LPI03253878

Publication Date:

March 24, 2025

Pages:

107

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Antivenom market size is predicted to grow from US$ 1057 million in 2025 to US$ 1365 million in 2031; it is expected to grow at a CAGR of 4.4% from 2025 to 2031.
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings. They are only recommended if there is significant toxicity or a high risk of toxicity. The specific antivenom needed depends on the species involved. It is given by injection.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.
The 鈥淎ntivenom Industry Forecast鈥� looks at past sales and reviews total world Antivenom sales in 2024, providing a comprehensive analysis by region and market sector of projected Antivenom sales for 2025 through 2031. With Antivenom sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antivenom industry.
This Insight Report provides a comprehensive analysis of the global Antivenom landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antivenom portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Antivenom market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antivenom and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antivenom.
This report presents a comprehensive overview, market shares, and growth opportunities of Antivenom market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Polyvalent antivenom
Monovalent antivenom
Segmentation by Application:
Non-profit Institutions
Hospitals and Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
Key Questions Addressed in this Report
What is the 10-year outlook for the global Antivenom market?
What factors are driving Antivenom market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Antivenom market opportunities vary by end market size?
How does Antivenom break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Antivenom Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Antivenom by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Antivenom by Country/Region, 2020, 2024 & 2031
2.2 Antivenom Segment by Type
2.2.1 Polyvalent antivenom
2.2.2 Monovalent antivenom
2.3 Antivenom Sales by Type
2.3.1 Global Antivenom Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Antivenom Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Antivenom Sale Price by Type (2020-2025)
2.4 Antivenom Segment by Application
2.4.1 Non-profit Institutions
2.4.2 Hospitals and Clinic
2.5 Antivenom Sales by Application
2.5.1 Global Antivenom Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Antivenom Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Antivenom Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Antivenom Breakdown Data by Company
3.1.1 Global Antivenom Annual Sales by Company (2020-2025)
3.1.2 Global Antivenom Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Antivenom Annual Revenue by Company (2020-2025)
3.2.1 Global Antivenom Revenue by Company (2020-2025)
3.2.2 Global Antivenom Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Antivenom Sale Price by Company
3.4 Key Manufacturers Antivenom Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Antivenom Product Location Distribution
3.4.2 Players Antivenom Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Antivenom by Geographic Region
4.1 World Historic Antivenom 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Antivenom Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Antivenom Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Antivenom 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Antivenom Annual Sales by Country/Region (2020-2025)
4.2.2 Global Antivenom Annual Revenue by Country/Region (2020-2025)
4.3 Americas Antivenom Sales Growth
4.4 APAC Antivenom Sales Growth
4.5 Europe Antivenom Sales Growth
4.6 Middle East & Africa Antivenom Sales Growth
5 Americas
5.1 Americas Antivenom Sales by Country
5.1.1 Americas Antivenom Sales by Country (2020-2025)
5.1.2 Americas Antivenom Revenue by Country (2020-2025)
5.2 Americas Antivenom Sales by Type (2020-2025)
5.3 Americas Antivenom Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antivenom Sales by Region
6.1.1 APAC Antivenom Sales by Region (2020-2025)
6.1.2 APAC Antivenom Revenue by Region (2020-2025)
6.2 APAC Antivenom Sales by Type (2020-2025)
6.3 APAC Antivenom Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Antivenom by Country
7.1.1 Europe Antivenom Sales by Country (2020-2025)
7.1.2 Europe Antivenom Revenue by Country (2020-2025)
7.2 Europe Antivenom Sales by Type (2020-2025)
7.3 Europe Antivenom Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Antivenom by Country
8.1.1 Middle East & Africa Antivenom Sales by Country (2020-2025)
8.1.2 Middle East & Africa Antivenom Revenue by Country (2020-2025)
8.2 Middle East & Africa Antivenom Sales by Type (2020-2025)
8.3 Middle East & Africa Antivenom Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Antivenom
10.3 Manufacturing Process Analysis of Antivenom
10.4 Industry Chain Structure of Antivenom
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Antivenom Distributors
11.3 Antivenom Customer
12 World Forecast Review for Antivenom by Geographic Region
12.1 Global Antivenom 麻豆原创 Size Forecast by Region
12.1.1 Global Antivenom Forecast by Region (2026-2031)
12.1.2 Global Antivenom Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Antivenom Forecast by Type (2026-2031)
12.7 Global Antivenom Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 CSL
13.1.1 CSL Company Information
13.1.2 CSL Antivenom Product Portfolios and Specifications
13.1.3 CSL Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 CSL Main Business Overview
13.1.5 CSL Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Antivenom Product Portfolios and Specifications
13.2.3 Merck Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 BTG
13.3.1 BTG Company Information
13.3.2 BTG Antivenom Product Portfolios and Specifications
13.3.3 BTG Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 BTG Main Business Overview
13.3.5 BTG Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Antivenom Product Portfolios and Specifications
13.4.3 Pfizer Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Haffkine Bio-Pharmaceutical
13.5.1 Haffkine Bio-Pharmaceutical Company Information
13.5.2 Haffkine Bio-Pharmaceutical Antivenom Product Portfolios and Specifications
13.5.3 Haffkine Bio-Pharmaceutical Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Haffkine Bio-Pharmaceutical Main Business Overview
13.5.5 Haffkine Bio-Pharmaceutical Latest Developments
13.6 Rare Disease Therapeutics
13.6.1 Rare Disease Therapeutics Company Information
13.6.2 Rare Disease Therapeutics Antivenom Product Portfolios and Specifications
13.6.3 Rare Disease Therapeutics Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Rare Disease Therapeutics Main Business Overview
13.6.5 Rare Disease Therapeutics Latest Developments
13.7 Flynn Pharma
13.7.1 Flynn Pharma Company Information
13.7.2 Flynn Pharma Antivenom Product Portfolios and Specifications
13.7.3 Flynn Pharma Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Flynn Pharma Main Business Overview
13.7.5 Flynn Pharma Latest Developments
13.8 Vins Bioproducts
13.8.1 Vins Bioproducts Company Information
13.8.2 Vins Bioproducts Antivenom Product Portfolios and Specifications
13.8.3 Vins Bioproducts Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Vins Bioproducts Main Business Overview
13.8.5 Vins Bioproducts Latest Developments
13.9 Bharat Serums and Vaccines
13.9.1 Bharat Serums and Vaccines Company Information
13.9.2 Bharat Serums and Vaccines Antivenom Product Portfolios and Specifications
13.9.3 Bharat Serums and Vaccines Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Bharat Serums and Vaccines Main Business Overview
13.9.5 Bharat Serums and Vaccines Latest Developments
13.10 Serum Biotech
13.10.1 Serum Biotech Company Information
13.10.2 Serum Biotech Antivenom Product Portfolios and Specifications
13.10.3 Serum Biotech Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Serum Biotech Main Business Overview
13.10.5 Serum Biotech Latest Developments
13.11 MicroPharm
13.11.1 MicroPharm Company Information
13.11.2 MicroPharm Antivenom Product Portfolios and Specifications
13.11.3 MicroPharm Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 MicroPharm Main Business Overview
13.11.5 MicroPharm Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.